186 related articles for article (PubMed ID: 20462440)
1. Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant.
Yu DD; Wang CT; Shi HS; Li ZY; Pan L; Yuan QZ; Leng F; Wen Y; Chen X; Wei YQ
J Exp Clin Cancer Res; 2010 May; 29(1):46. PubMed ID: 20462440
[TBL] [Abstract][Full Text] [Related]
2. Enhanced tumor radiosensitivity by a survivin dominant-negative mutant.
Yuan QZ; Wang CT; Mao YQ; Zhang P; Shi HS; Li ZY; Pan L; Yu DD; Leng F; Chen X; Ying W; Xu JH; Li W; Wu F; Wen Y; Ma TT; Wei YQ
Oncol Rep; 2010 Jan; 23(1):97-103. PubMed ID: 19956869
[TBL] [Abstract][Full Text] [Related]
3. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant.
Peng XC; Yang L; Yang LP; Mao YQ; Yang HS; Liu JY; Zhang DM; Chen LJ; Wei YQ
J Exp Clin Cancer Res; 2008 Sep; 27(1):46. PubMed ID: 18816410
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin.
Tian H; Liu S; Zhang J; Zhang S; Cheng L; Li C; Zhang X; Dail L; Fan P; Dai L; Yan N; Wang R; Wei Y; Deng H
J Biomed Nanotechnol; 2012 Aug; 8(4):633-41. PubMed ID: 22852473
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
Xiao W; Chen X; Yang L; Mao Y; Wei Y; Chen L
Int J Pharm; 2010 Jun; 393(1-2):119-26. PubMed ID: 20416367
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of lymphatic metastases by a survivin dominant-negative mutant.
Xu GC; Zhang P; Leng F; Pan L; Li ZY; Yu DD; Shan Y; Yuan QZ; Wen Y; Mu B; Shi HS; Chen X; Wang CT
Oncol Res; 2012; 20(12):579-87. PubMed ID: 24139416
[TBL] [Abstract][Full Text] [Related]
7. [Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells].
Zhang MC; Hu CP; Chen Q
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):408-12. PubMed ID: 17152483
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer.
Pan L; Peng XC; Leng F; Yuan QZ; Shan Y; Yu DD; Li ZY; Chen X; Xiao WJ; Wen Y; Ma TT; Yang L; Mao YQ; Yang HS; Wei YQ; Wang CT
J Cancer Res Clin Oncol; 2011 Jan; 137(1):19-28. PubMed ID: 20217127
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of mSurvivinThr34→Ala in murine colon carcinoma when administered intravenously.
Li HX; Zhao XY; Wang L; Wang YS; Kan B; Xu JR; Li J; Wen YJ; Peng XC; Chen X; Yan F; Ye B; Du XB; Zhao JM; Yi T; Chen XC; Du XX; Wei YQ; Zhao X
Med Oncol; 2010 Dec; 27(4):1156-63. PubMed ID: 19949901
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation.
Belyanskaya LL; Hopkins-Donaldson S; Kurtz S; Simões-Wüst AP; Yousefi S; Simon HU; Stahel R; Zangemeister-Wittke U
Int J Cancer; 2005 Dec; 117(5):755-63. PubMed ID: 15981204
[TBL] [Abstract][Full Text] [Related]
12. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.
Zhou HJ; Zhang JL; Li A; Wang Z; Lou XE
Cancer Chemother Pharmacol; 2010 May; 66(1):21-9. PubMed ID: 19756601
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between survivin expression and chemosensitivity of human lung cancer cells].
Yang H; Fu JH; Hu Y; Huang WZ; Zheng B; Wang G
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(27):1934-7. PubMed ID: 17923022
[TBL] [Abstract][Full Text] [Related]
14. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
[TBL] [Abstract][Full Text] [Related]
15. Enhanced efficacy of combination therapy with adeno‑associated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of Lewis lung carcinoma.
He SS; Wu QJ; Gong CY; Luo ST; Zhang S; Li M; Lu L; Wei YQ; Yang L
Mol Med Rep; 2014 Jun; 9(6):2069-76. PubMed ID: 24714917
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
17. Suppression of lung cancer in murine model: treated by combination of recombinant human endostsatin adenovirus with low-dose cisplatin.
Bai RZ; Wu Y; Liu Q; Xie K; Wei YQ; Wang YS; Liu K; Luo Y; Su JM; Hu B; Liu JY; Li Q; Niu T; Zhao ZW; Yang L
J Exp Clin Cancer Res; 2009 Mar; 28(1):31. PubMed ID: 19265510
[TBL] [Abstract][Full Text] [Related]
18. [Anti-prostate cancer activity of Survivin-T34A mutant in vitro and in vivo].
Pan L; Peng XC; Yuan QZ; Leng F; Yu DD; Shan Y; Li ZY; Wang CT
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 May; 41(3):390-3. PubMed ID: 20629305
[TBL] [Abstract][Full Text] [Related]
19. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients.
Nakamura M; Tsuji N; Asanuma K; Kobayashi D; Yagihashi A; Hirata K; Torigoe T; Sato N; Watanabe N
Cancer Sci; 2004 Jan; 95(1):44-51. PubMed ID: 14720326
[TBL] [Abstract][Full Text] [Related]
20. Influence of SiRNA targeting survivin on chemosensitivity of H460/cDDP lung cancer cells.
Yang H; Fu JH; Hu Y; Huang WZ; Zheng B; Wang G; Zhang X; Wen J
J Int Med Res; 2008; 36(4):734-47. PubMed ID: 18652770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
